the key recommendations. For a complete list of recommendations, please refer to the Results section of the text. For the level of evidence supporting each recommendation, see Table 1 Very low Conditional recommendation based on very-low-quality evidence; may consider MTX and an IL-12/23i biologic combination therapy if the patient has severe skin manifestations, has had a partial response to current MTX therapy, or has concomitant uveitis (since uveitis may respond to MTX therapy). * Active